Cowealth Medical China Co., Ltd. Class A

Cowealth Medical China Co., Ltd. Class A

SSSE:603122
9.88
CNY
-0.48
(-4.63%)
-0.07EPS
5.52BMarket Cap
Cowealth Medical China Co., Ltd. Class A
SSE:603122
(Shanghai Stock Exchange)

Recent

price

9.88

P/E

ratio

- -

div

yld

0.02%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.28
2.27
4.05
3.6
4.01
3.4
2.78
2.38
1.61
1.59
Revenue per Share
0.16
0.17
0.26
0.24
0.27
0.22
0.12
0.07
-0.08
-0.07
Basic EPS, GAAP
-0.03
-0.23
-0.25
0.22
-0.05
-0.15
-0.14
0.26
0.01
- -
Free Cash Flow per Basic Share
- -
0.03
0.16
0.15
0.27
0.2
0.17
0.07
0.13
- -
Dividend per Share
1.37
1.26
2.64
2.4
2.67
2.96
2.93
2.94
2.66
2.61
Book Value per Share
1.36
1.25
2.64
2.4
2.66
2.95
2.91
2.92
2.64
2.6
Tangible Book Value per Share
299
398
258
302
297
376
393
394
421
402
Basic Weighted Avg Shares
680
904
1,047
1,089
1,191
1,280
1,093
939
678
640
Sales/Revenue/Turnover
9.07
11.36
11.05
10.68
9.46
8.78
6.19
3.84
-3.47
-1.95
Operating Margin (%)
25
24
19
16
15
12
12
10
10
- -
Depreciation Expense
47
67
67
73
80
83
47
28
-34
-27
Net Income, GAAP
27.68
27.79
27.46
26.39
26.8
27.34
28.21
27.86
- -
- -
Effective Tax Rate (%)
6.89
7.4
6.41
6.66
6.74
6.46
4.32
2.94
-4.96
-4.2
Profit Margin (%)
265
260
655
593
668
1,050
969
972
757
731
Working Capital
- -
14
10
17
20
17
6
1
2
1
LT Debt
408
375
789
717
796
1,179
1,169
1,175
1,060
1,042
Total Equity
- -
14.37
9.9
9.14
9.45
7.94
3.96
2.4
- -
- -
Return on Invested Capital (%)
- -
15.38
10.42
8.71
9.44
7.85
4.11
2.36
- -
- -
Return on Capital (%)
- -
17.1
11.54
9.63
10.61
8.38
4.03
2.36
-3.02
-2.5
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
93
30
35
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
398
398
398
Market Capitalization
6,910
4,363
5,517

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,116
1,133
1,128
Cash, Cash Equivalents & STI
116
128
140
Accounts Receivable, Net
696
721
749
Inventories
166
164
162
Total Current Liabilities
366
383
396
Payables & Accruals
- -
- -
- -
ST Debt
93
30
35
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.79%
-9.79%
Free Cash Flow
- -
-44.84%
-96.56%
Net Income, GAAP
- -
-58.58%
-222.04%
Sales/Revenue/Turnover
- -
-7.94%
-27.83%
Total Cash Common Dividend
- -
18.05%
95.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
239
242
230
228
939
2025
176
192
- -
129
678
2026
154
184
172
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.04
0.01
- -
0.07
2025
-0.02
- -
- -
-0.05
-0.08
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.06
- -
- -
0.07
2025
- -
- -
- -
- -
0.13
2026
- -
- -
- -
- -
- -
Business
Cowealth Medical China Co., Ltd. is a healthcare services and medical technology provider that specializes in in-vitro diagnostic supply chain integration, medical equipment distribution, and digital hospital empowerment solutions across Greater China. Founded in 1997 and headquartered in Shanghai, China, the company operates as a publicly listed subsidiary of Taiwan-based Cowealth Medical Holding Co., Ltd. and primarily serves tertiary Grade-A hospitals and healthcare institutions across Mainland China. The company organizes its business operations across three core segments: In-Vitro Diagnostic Centralized Procurement Services, Medical Equipment Distribution, and Healthcare Enablement and Digital Solutions. Its product and service portfolio encompasses: centralized procurement, vendor-managed inventory, and supply chain logistics for multi-brand in-vitro diagnostic reagents and consumables, covering clinical chemistry, immunodiagnostics, hematology, point-of-care testing, molecular diagnostics, microbiology, and blood screening; agency distribution, import, installation, and technical support for advanced specialized medical devices, including radiation oncology equipment, ophthalmic diagnostic systems, and surgical apparatus; the Zhibeita hospital operational decision-support and financial integration software platform; the MetaVision digitized operating room audio-video integration platform for live surgical tele-mentoring, clinical teaching, and research; specialized artificial intelligence-driven diagnostic support systems for rheumatology and ocular surface diseases; and hospital management consulting alongside cross-strait medical academic exchange services. In recent developments, Cowealth Medical China has accelerated its strategic transition from a conventional medical distributor to a technology-driven hospital empowerment partner through the rollout of its ACME service framework. The company has expanded commercial deployments of its proprietary Zhibeita healthcare management platform and MetaVision digital operating room systems across regional medical centers. In response to nationwide Volume-Based Procurement policies affecting diagnostic reagent pricing, the company restructured its centralized supply chain workflows, enhanced hospital-level SPD logistics management, and increased research and development investment to commercialize proprietary medical informatics software and clinical decision-support algorithms. Additionally, the company has broadened its partnerships with domestic hospital departments to deploy specialized clinical artificial intelligence diagnostic solutions, driving operational efficiency and supporting financial recovery across its core institutional customer base.